Abstract
In this issue of Blood, Connors et al report promising 5-year outcomes that support the replacement of bleomycin with brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the front-line treatment of patients with advanced-stage Hodgkin lymphoma.1.
Cite
CITATION STYLE
APA
Stephens, D. M. (2017, September 14). Brentuximab: Is it time for a new “B” in ABVD? Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-08-798553
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free